Quintiles Expects Increase In Phase IV Business Following Vioxx Withdrawal
This article was originally published in The Pink Sheet Daily
Executive Summary
The company could see an “uptick” in late-phase study contracts based on internal initiatives and market dynamics from the Vioxx withdrawal, CFO Ratliff tells analysts.
You may also be interested in...
Senate Vioxx Hearing To Include Merck’s Gilmartin, FDA’s Crawford
A Nov. 18 Senate Finance Committee hearing on the withdrawal of Vioxx will include testimony from Merck CEO Ray Gilmartin
NME Slowdown Shows Market Pressure On Me-Toos, Not FDA Caution – Lutter
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter
Amgen Aranesp, Vectibix Setbacks Illustrate Risks Of Real World Trials
Amgen's failed Anemia of Cancer trial of Aranesp and Panitumumab Advanced Colorectal Cancer Evaluation (PACCE) trial of Vectibix may illustrate the potential pitfalls facing sponsors that conduct "real world" trials of their products